Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Salarius Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q2 2025 | 1 | -$2.20 | -$2.20 | -$2.20 |
| Q3 2025 | 1 | -$2.24 | -$2.24 | -$2.24 |
| Q4 2025 | 1 | -$2.33 | -$2.33 | -$2.33 |
Salarius Pharmaceuticals, Inc. Earnings Date And Information
Salarius Pharmaceuticals, Inc. last posted its earnings results on Friday, March 21st, 2025. The company reported $-0.66 earnings per share for the quarter, topping analysts' consensus estimates of $-2.31 by $1.65. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Salarius Pharmaceuticals, Inc. has generated $-6 earnings per share over the last year ($-5.79 diluted earnings per share) and currently has a price-to-earnings ratio of -0.15. Salarius Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based on prior year's report dates.
Salarius Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/21/2025 | Q4 2024 | -$2.31 | -$1.52 | 0.79 | $0 | $0 |
| 11/14/2024 | Q3 2024 | -$2.40 | -$0.76 | 1.64 | $0 | $0 |
| 08/09/2024 | Q2 2024 | -$53.60 | -$2.37 | 51.23 | $0 | $0 |
| 05/13/2024 | Q1 2024 | -$53.60 | -$3.27 | 50.33 | N/A | $0 |
| 03/22/2024 | Q4 2023 | -$8.08 | -$0.22 | 7.86 | N/A | $17,892 |
| 11/09/2023 | Q3 2023 | -$8.56 | -$0.65 | 7.91 | N/A | $0 |
| 08/10/2023 | Q2 2023 | -$10.08 | -$1.43 | 8.65 | N/A | $0 |
| 05/11/2023 | Q1 2023 | -$15.84 | -$2.20 | 13.64 | N/A | $0 |
| 03/27/2023 | Q4 2022 | -$16.56 | -$2.88 | 13.68 | N/A | $0 |
| 11/10/2022 | Q3 2022 | -$22.80 | -$6.38 | 16.42 | N/A | $0 |
| 08/05/2022 | Q2 2022 | N/A | -$2.20 | N/A | N/A | $0 |
| 05/12/2022 | Q1 2022 | -$2.25 | -$3.29 | -1.04 | N/A | $0 |
| 03/25/2022 | Q4 2021 | N/A | -$2.27 | N/A | N/A | $-1,840,216 |
| 11/04/2021 | Q3 2021 | -$18.00 | -$2.09 | 15.91 | $1.28 M | $0 |
| 08/05/2021 | Q2 2021 | -$12.00 | -$1.72 | 10.28 | $1.37 M | $571,387 |
| 05/12/2021 | Q1 2021 | -$1.25 | -$1.52 | -0.27 | N/A | $1.27 M |
| 03/18/2021 | Q4 2020 | N/A | -$2.84 | N/A | N/A | $1.48 M |
| 11/12/2020 | Q3 2020 | N/A | -$2.39 | N/A | $1.19 M | $1.38 M |
| 08/12/2020 | Q2 2020 | -$4.00 | -$3.20 | 0.8 | $1.39 M | $1.24 M |
| 05/14/2020 | Q1 2020 | -$11.00 | -$5.46 | 5.54 | N/A | $1.13 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Salarius Pharmaceuticals, Inc. Earnings: FAQ's
Salarius Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 12th, 2025 based offlast year's report dates.
In the previous quarter, Salarius Pharmaceuticals, Inc. (:SLRX) reported $-0.66 earnings per share (EPS) to beat the analysts' consensus estimate of $-2.31 by $1.65.
The conference call for Salarius Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Salarius Pharmaceuticals, Inc.'s latest earnings report can be read online.
Salarius Pharmaceuticals, Inc. (:SLRX) has a recorded net income of $-5,575,777.Salarius Pharmaceuticals, Inc. has generated $-5.79 earnings per share over the last four quarters.
Salarius Pharmaceuticals, Inc. (:SLRX) has a price-to-earnings ratio of -0.15 and price/earnings-to-growth ratio is 0.01.